SLAMF7 and Miyoshi myopathy: More recently, the ELOQUENT-2 phase III trial indicated prolonged progression-free survival and a higher frequency of remission in MM patients that received the monoclonal antibody elotuzumab directed against the “signaling lymphocytic activation molecule family member 7” (SLAMF7) in addition to standard induction treatment [16].